Trevena Inc

NASDAQ:TRVNUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

Contact Information

Headquarters

955 Chesterbrook Boulevard, Suite 110CHESTERBROOK, PA, United States 19087

Phone

610-354-8840

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Carrie Bourdow

Chief Financial Officer, Chief Operating Officer, Executive Vice President

Barry Shin

Senior Vice President, Chief Medical Officer

Mark Demitrack

Senior Vice President and Chief Commercial Officer

Patricia Drake

Senior Vice President, Chief Business Officer and Head - Commercial Operations

Robert Yoder